John Xu
AstraZeneca (Switzerland)(CH)AstraZeneca (Finland)(FI)AstraZeneca (Canada)(CA)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Pancreatic function and diabetes, Metabolism, Diabetes, and Cancer, Diabetes and associated disorders
Most-Cited Works
- → Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma(2013)590 cited
- → Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial(2017)289 cited
- → Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study(2018)229 cited
- → Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function(2017)150 cited
- → Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials(2020)76 cited
- → Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2(2019)48 cited